Rekayasa Model Sistem Informasi Web Sertifikasi Kompetensi Di Lembaga Sertifikasi Profesi Menggunakan Metodologi Modeldriven Uwe (Uml-based Web Engineering)

Tenaga kerja Indonesia yang kompeten semakin penting menjelang pelaksanaan Asean Economic Community (AEC) pada tahun 2015. Pemerintah memastikan kompetensi tenaga kerja melalui program sertifikasi kompetensi yang dilaksanakan oleh Lembaga Sertifikasi Profesi (LSP) yang ditunjuk oleh BNSP (Badan Nasional Sertifikasi Profesi). LSP bertanggung jawab terhadap pengembangan standar kompetensi, sertifikasi kompetensi, dan pelaksana akreditasi Tempat Uji Kompetensi (TUK). Sistem manajemen berteknologi informasi diperlukan untuk mendukung operasional LSP agar efisien, cepat, dan produktif. Sistem web telah menjadi salah satu platform yang paling sering digunakan sebagai basis suatu sistem. Pendekatan pengembangan model-driven diyakini paling tepat untuk rekayasa web. Metode pendekatan sistem yang digunakan yaitu UWE (UML-Based Web Engineering) karena kompatibilitasnya dengan alat UML yang sudah akrab di kalangan pengembang sistem dan mencakup seluruh siklus pengembangan. Penelitian ini menghasilkan suatu alternatif model sistem manajemen sertifikasi kompetensi dan lisensi LSP yang dengan pendekatan model-driven rancangan sistem bersifat flesibel sehingga relatif mudah penerapannya diberbagai LSP yang meskipun sebagian besar struktur dan prosedur sertifikasinya sama tetapi tetap ada keunikan di masing-masing LSP. Data penelitian diperoleh dari sejumlah LSP, asesor, asesi, dan TUK

Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicentre, randomised trial (SUMIT)

Purpose: Uveal melanoma is the most common primary intraocular malignancy in adults with no effective systemic treatment option in the metastatic setting. Selumetinib (AZD6244, ARRY-142886) is an oral, potent, and selective MEK1/2 inhibitor with a short half-life, which demonstrated single-agent activity in patients with metastatic uveal melanoma in a randomized phase II trial. Methods: The Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) study was a phase III, double-blind trial (ClinicalTrial.gov identifier: NCT01974752) in which patients with metastatic uveal melanoma and no prior systemic therapy were randomly assigned (3:1) to selumetinib (75 mg twice daily) plus dacarbazine (1,000 mg/m2 intravenously on day 1 of every 21- day cycle) or placebo plus dacarbazine. The primary end point was progression-free survival (PFS) by blinded independent central radiologic review. Secondary end points included overall survival and objective response rate. Results: A total of 129 patients were randomly assigned to receive selumetinib plus dacarbazine (n = 97) or placebo plus dacarbazine (n = 32). In the selumetinib plus dacarbazine group, 82 patients (85%) experienced a PFS event, compared with 24 (75%) in the placebo plus dacarbazine group (median, 2.8 v 1.8 months); the hazard ratio for PFS was 0.78 (95% CI, 0.48 to 1.27; two-sided P = .32). The objective response rate was 3% with selumetinib plus dacarbazine and 0% with placebo plus dacarbazine (two-sided P = .36). At 37% maturity (n = 48 deaths), analysis of overall survival gave a hazard ratio of 0.75 (95% CI, 0.39 to 1.46; two-sided P = .40). The most frequently reported adverse events (selumetinib plus dacarbazine v placebo plus dacarbazine) were nausea (62% v 19%), rash (57% v 6%), fatigue (44% v 47%), diarrhea (44% v 22%), and peripheral edema (43% v 6%). Conclusion: In patients with metastatic uveal melanoma, the combination of selumetinib plus dacarbazine had a tolerable safety profile but did not significantly improve PFS compared with placebo plus dacarbazine

Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study.

n/